Francois Carbonnel - Amgen Insider

AMGN -- USA Stock  

USD 185.01  1.06  0.58%

Independent Director

Mr. Francois de Carbonnel is an Independent Director of Amgen Inc. Franois de Carbonnel is a director of corporations and corporate advisor. Mr. de Carbonnel was a member of the group governance council of Mazars Group, a privatelyheld international organization specializing in audit, accountancy, tax, legal and advisory services, from December 2011 to January 2016. From 2004 to May 2015, Mr. de Carbonnel was a director of Solocal Group, a French company which offers online content, advertising solutions and transactional services, and served as Chairman of the Remuneration and Appointments Committee. From 2004 until October 2013, Mr. de Carbonnel was a director of a number of funds managed by Ecofin, a privatelyheld investment management firm. Mr. de Carbonnel was a director of Thomson S.A., a French multimedia corporation, from 2007 to January 2010, serving as Chairman of the Audit Committee throughout his tenure, and as nonexecutive Chairman of the Board from April 2008 to April 2009. Mr. de Carbonnel was a director of Quilvest S.A., a Luxembourg company which provides wealth management and private equity services, from 2006 to 2013.
Age: 69  Director Since 2008      
805-447-1000  http://www.amgen.com

Management Efficiency

The company has return on total asset (ROA) of 8.84 % which means that it generated profit of $8.84 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 9.59 % meaning that it created $9.59 on every $100 dollars invested by stockholders.
The company currently holds 35.54 B in liabilities with Debt to Equity (D/E) ratio of 227.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen has Current Ratio of 3.8 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Pamela CraigMerck Co
2015
Raul AlvarezEli Lilly and Company
2009
Kneeland YoungbloodMallinckrodt Public Limited Com
2013
Nancy HutsonEndo International plc
2009
Christopher CoughlinAllergan plc
2016
Theodore SamuelsBristol Myers Squibb Company
2017
Inge ThulinMerck Co
2018
Roxanne AustinAbbott Laboratories
2000
Michelle KumbierAbbott Laboratories
2018
Karen HornEli Lilly and Company
2012
William MontagueEndo International plc
2009
Angus RussellMallinckrodt Public Limited Com
2018
Joel McCombBio Rad Laboratories
2014
Shane CookeEndo International plc
2014
Robert AlpernAbbott Laboratories
2008
Catherine KlemaAllergan plc
2016
Sharad MansukaniEndo International plc
2017
Thomas GlocerMerck Co
2007
Michael GrobsteinBristol Myers Squibb Company
2007
Jeffrey EdwardsBio Rad Laboratories
2017
Rochelle LazarusMerck Co
2004

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ. It employs 20800 people.Amgen (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Amgen Leadership Team

Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance Indicators

Did you try this?

Run Equity Forecasting Now
   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Equity Forecasting

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Amgen and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.